The WHO’s COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) today announced the completion of a licensing deal for COVID-19 serological antibody technology with the Spanish National Research Council (CSIC). Anti-SARS-CoV-2 antibodies generated in response to a COVID-19 infection or a vaccination are efficiently checked with this test. This is the first transparent, global, non-exclusive COVID-19 health tool license, as well as the first test license signed by MPP and put in the WHO Pool.
The license’s goal is to speed up the manufacturing and commercialization of CSIC’s COVID-19 serological test around the world. The agreement covers all associated patents as well as the biological material required for the test’s production. MPP and/or potential licensees will receive all necessary know-how as well as training from CSIC. For low- and middle-income nations, the license will be royalty-free and will run until the final patent expires.
To date, technology has yielded four separate tests, one of which has the capacity to identify the immune response of COVID-19 infected people from those who have been vaccinated. This should improve future research into immunity’s level and duration, as well as the effectiveness of the tools at our disposal.
The tests are easy to use and can be used in any location that has a basic laboratory infrastructure, such as rural areas in low- and middle-income nations. The reading can be done manually (by comparing the color of the wells to the color chart with the naked eye), but an ELISA reader is advised for improved accuracy.
If the test is to be sold in low- and middle-income nations, promising performance data in the European population will need to be provided by the firms developing the technology.